Stratatech begins phase 3 clinical trials of skin substitute

Stratatech, founded by Professor Lynn Allen-Hoffmann, has entered phase 3 clinical trials to prove that their regenerative skin tissue, StrataGraft, is safe and effective for treating severe burns. StrataGraft is a viable, full-thickness skin substitute designed to mimic natural human skin and was developed from cells originally isolated and characterized in the laboratory of Dr. Allen-Hoffmann at the University of Wisconsin School of Medicine and Public Health. StrataGraft skin tissue is now entering the final stage required for FDA approval for its use in the treatment of thermal burn injuries.
Stratatech, founded by Dr. Allen-Hoffmann in 2000, was purchased in 2016 by Mallinckrodt Pharmaceuticals based in the UK, but remains at University Research Park in Madison.